NASDAQ$ANGO
AngioDynamics Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Announced fiscal year 2024 third quarter results and updated fiscal year 2024 guidance to reflect asset divestiture.
AngioDynamics reported an 8.0% increase in net sales to $66.0 million for the third quarter of fiscal year 2024, driven by growth in both Med Tech and Med Device portfolios. The company completed the sale of its PICC and Midline product portfolios and reached a settlement agreement with BD/Bard. They also received FDA 510(k) clearance for AlphaVac in the treatment of pulmonary embolism.
- Completed the sale of its PICC and Midline product portfolios to Spectrum Vascular on February 15, 2024.
- Pro forma net sales increased 8.0% to $66.0 million.
- Pro forma Med Tech net sales increased 12.6%.
- Subsequent to quarter end, the Company received 510(k) clearance for the use of AlphaVac to treat pulmonary embolism
Headline financials
Revenue & EPS history
AngioDynamics · Revenue · Quarterly
$75.2M
Revenue by segment
AngioDynamics · $78.7M total across 2 segments · Q1 2024
- Med Device$52.8M-10.0%67.1%
- Med Tech$25.9M+13.4%32.9%
Forward guidance
The Company now expects its fiscal year 2024 net sales to be in the range of $270 to $275 million, expects gross margin to be approximately 52.0% to 54.0% and adjusted loss per share in the range of $0.54 to $0.58.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2024
-0.9%
Avg return
Earnings day
-2.4%
Avg return
5 days after
-3.7%
Avg return
30 days after
43%
28 / 65 earnings
Positive
+30.9%
Q2 2025
Best reaction
-26.2%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | +5.0% | -5.0% | — | |
| Q2 2026 | -13.5% | -25.5% | -24.0% | |
| Q1 2026 | +6.1% | -0.2% | +8.7% | |
| Q4 2025 | -10.2% | -9.8% | -9.3% | |
| Q3 2025 | +12.4% | -3.6% | -3.8% | |
| Q2 2025 | +30.9% | +32.6% | +17.4% | |
| Q1 2025 | -20.3% | -23.1% | -12.7% | |
| Q4 2024 | +24.8% | +21.1% | +25.8% | |
| Q3 2024 | +15.6% | +14.6% | +3.1% | |
| Q2 2024 | -17.7% | -20.1% | -23.5% | |
| Q1 2024 | -5.9% | -7.2% | -10.4% | |
| Q4 2023 | -2.5% | -3.8% | -16.1% | |
| Q3 2023 | -17.1% | -23.3% | -33.3% | |
| Q2 2023 | +11.5% | -1.0% | -1.3% | |
| Q1 2023 | -26.2% | -38.0% | -34.8% | |
| Q4 2022 | +4.4% | +6.4% | +21.3% | |
| Q3 2022 | +9.8% | +7.2% | -8.7% | |
| Q2 2022 | -15.5% | -15.5% | -25.8% | |
| Q1 2022 | +12.6% | +17.8% | +22.4% | |
| Q4 2021 | -7.0% | -8.6% | -3.9% | |
| Q3 2021 | +12.3% | +11.1% | +16.3% | |
| Q2 2021 | +14.7% | +14.2% | +24.7% | |
| Q1 2021 | +13.0% | +7.8% | -0.1% | |
| Q4 2020 | -11.5% | -11.8% | -12.7% | |
| Q3 2020 | -2.7% | +2.3% | -0.6% | |
| Q2 2020 | -9.2% | -11.3% | -17.0% | |
| Q1 2020 | -17.6% | -17.6% | -13.7% | |
| Q4 2019 | +6.8% | +6.2% | -4.8% | |
| Q3 2019 | -7.7% | -8.2% | -18.4% | |
| Q2 2019 | +6.7% | +6.7% | +8.6% | |
| Q1 2019 | -10.3% | -12.9% | -17.0% | |
| Q4 2018 | -9.2% | -7.8% | -5.4% | |
| Q3 2018 | +3.2% | +8.9% | +16.4% | |
| Q2 2018 | -1.8% | -0.1% | +5.1% | |
| Q1 2018 | -8.9% | -9.1% | -8.4% | |
| Q4 2017 | -5.9% | -3.5% | +5.1% | |
| Q3 2017 | +0.3% | -1.3% | -10.2% | |
| Q2 2017 | +1.7% | +3.2% | -2.5% | |
| Q1 2017 | -4.5% | -0.1% | -8.4% | |
| Q4 2016 | +10.6% | +14.1% | +8.4% | |
| Q3 2016 | -2.1% | — | — | |
| Q2 2016 | -8.7% | — | — | |
| Q1 2016 | -8.8% | — | — | |
| Q4 2015 | -2.3% | — | — | |
| Q3 2015 | -6.1% | — | — | |
| Q2 2015 | -0.9% | — | — | |
| Q1 2015 | +3.8% | — | — | |
| Q4 2014 | -5.0% | — | — | |
| Q3 2014 | -1.5% | — | — | |
| Q2 2014 | +6.1% | — | — | |
| Q1 2014 | +5.3% | — | — | |
| Q4 2013 | +1.3% | — | — | |
| Q3 2013 | -7.4% | — | — | |
| Q2 2013 | -2.4% | — | — | |
| Q1 2013 | -8.8% | — | — | |
| Q4 2010 | -0.9% | — | — | |
| Q4 2012 | +4.0% | — | — | |
| Q3 2011 | -1.3% | — | — | |
| Q3 2012 | -1.3% | — | — | |
| Q2 2012 | -5.7% | — | — | |
| Q2 2011 | -5.7% | — | — | |
| Q1 2011 | +3.5% | — | — | |
| Q4 2011 | +3.5% | — | — | |
| Q1 2012 | +3.5% | — | — | |
| Q3 2010 | +0.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro